OR WAIT null SECS
BioMed X and Boehringer Ingelheim have announced the start of a new research project in brain sensor development.
BioMed X, a German independent research institute, announced on March 1, 2022 the launch of its new research project ‘Advanced Biomarker Detection for Pharmaceutical Monitoring in the Brain’ (BDB) in collaboration with Boehringer Ingelheim.
The goal of BDB is to develop a continuous monitoring biosensor to detect small-molecule biomarkers in rodent brain tissue to support the development of innovative treatment approaches in precision psychiatry. The BDB project is the fifth collaborative research project between BioMed X and Boehringer Ingelheim, who have worked on projects together since 2014.
“The process of developing active drugs for the treatment of neuropsychiatric diseases involves establishing a robust relationship between the pharmacodynamic effect and the pharmacokinetic parameters of new drug candidates,”said group leader of team BDB, Dr. Khulan Sergelen. “Our main task is the development of a new minimally invasive molecular biosensor, including molecular design and assay development, biocompatible sensor architecture, and optical sensor integration for in vivo monitoring.”
“The new project will further strengthen and significantly extend our institute’s expertise and capabilities in the field of neuroscience and sensor development,” added Christian Tidona, founder and managing director of BioMed X. “We are eager to add another success story to our long-term partnership with Boehringer Ingelheim and with this new technology platform we are looking forward to contributing to the discovery of new biology in neuropsychiatric diseases.”
Source: BioMed X